Tempus AI (NASDAQ:TEM) Sees Unusually-High Trading Volume on Analyst Upgrade

Tempus AI, Inc. (NASDAQ:TEM) shares saw unusually-high trading volume on Thursday after BTIG Research raised their price target on the stock from $70.00 to $80.00. BTIG Research currently has a buy rating on the stock. Approximately 4,573,710 shares changed hands during mid-day trading, a decline of 21% from the previous session’s volume of 5,825,256 shares.The stock last traded at $66.2140 and had previously closed at $61.25.

A number of other analysts have also recently weighed in on TEM. HC Wainwright lowered their price target on Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a research report on Monday, August 3rd. Wolfe Research began coverage on Tempus AI in a report on Tuesday, June 2nd. They set a “peer perform” rating for the company. TD Cowen restated a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Guggenheim boosted their target price on shares of Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Finally, Weiss Ratings raised shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. Nine analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Tempus AI presently has a consensus rating of “Hold” and a consensus price target of $65.69.

Insiders Place Their Bets

In related news, CFO James William Rogers sold 11,529 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $55.00, for a total transaction of $634,095.00. Following the transaction, the chief financial officer owned 114,866 shares in the company, valued at $6,317,630. This represents a 9.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jennifer A. Doudna sold 2,673 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $55.00, for a total transaction of $147,015.00. Following the sale, the director directly owned 25,942 shares in the company, valued at approximately $1,426,810. This represents a 9.34% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 684,424 shares of company stock valued at $33,255,565. 24.26% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Pictet Asset Management Holding SA boosted its holdings in Tempus AI by 291.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock valued at $2,948,000 after acquiring an additional 36,096 shares during the last quarter. Bogart Wealth LLC lifted its position in Tempus AI by 365,087.5% during the 4th quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock valued at $3,450,000 after purchasing an additional 58,414 shares during the period. Eagle Health Investments LP bought a new position in shares of Tempus AI in the 1st quarter valued at about $11,588,000. Alethea Capital Management LLC bought a new position in shares of Tempus AI in the 4th quarter valued at about $1,863,000. Finally, Hussman Strategic Advisors Inc. grew its position in shares of Tempus AI by 100.0% during the 4th quarter. Hussman Strategic Advisors Inc. now owns 42,000 shares of the company’s stock worth $2,480,000 after buying an additional 21,000 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Stock Performance

The stock’s 50 day moving average is $52.10 and its two-hundred day moving average is $51.16. The firm has a market capitalization of $11.81 billion, a P/E ratio of -45.47 and a beta of 3.58. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16.

Tempus AI (NASDAQ:TEM) last released its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.22) EPS. As a group, equities analysts anticipate that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.